- call +1-201-465-4211
- email sales@mrinsights.biz
Circulating tumor cells are significantly useful in determining the status of disease progression rate and projection of therapy needed for tumor eradication. Further development of various tumor markers that can be used along with companion diagnostics to diagnose or monitor various forms of cancer are expected to boost usage rates of CTC tests in the coming years.
Circulating tumor cell detection test possesses the ability to detect, quantify, and analyze tumor cells in the blood of cancer patients. It includes enrichment, detection and analysis of the detected circulating tumor cells. Circulating tumor cells tests are applicable in the characterization of tumor cells through biochemical marker analysis. CTC isolation, detection, and molecular characterization systems find investigational application in prostate, breast, colon, head, neck, skin, lung, and pancreatic cancer
Growing incidences oncology diseases and the introduction of novel biotechnological methods that enable the isolation and quantitation of circulating tumor cells. Furthermore, other factors like early disease diagnosis, cost savings on multiple treatments, drug safety, patient compliance, and optimization of therapies are attributive for rising demand for the preventive medicine, thus influencing the demand for CTC tests.
On course of the forecast period it is expected that over 150 companion diagnostic on-label combinations and a range of personalized therapeutic drugs under clinical trials and development pipelines based on companion diagnostics. The level of adoption of companion diagnostics is expected to significantly increase after these obtain complete FDA approval and are commercialized fully.
Scope of the Report:
This report focuses on the Circulating Tumor Cell Diagnostics in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The worldwide market for Circulating Tumor Cell Diagnostics is expected to grow at a CAGR of roughly 9.2% over the next five years, will reach 8460 million US$ in 2023, from 4990 million US$ in 2017, according to a new study.
Market Segment by Manufacturers, this report covers
Janssen Diagnostics
Advanced Cell Diagnostics
Aviva Biosciences
Biocept Inc
Biofluidica Inc.
CellTraffix Inc.
Clearbridge BioMedics Pte Ltd
Epic Sciences Inc.
Fluxion Biosciences Inc.
ScreenCell
Silicon Biosystems
Sysmex Corporation
Greiner Bio-One GmbH
AdnaGen AG
Apocell Inc
Biocep Ltd
Canopus Bioscience Ltd
Creatv Microtech Inc
Ikonisys Inc
IV Diagnostics Inc
Miltenyi Biotech GmbH
Nanostring Technologies Inc
Rarecells Diagnostics.
Vitatex Inc
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
CTC Enrichment
CTC Detection
CTC Analysis
Market Segment by Applications, can be divided into
Tumorigenesis research
EMT biomarkers development
Cancer stem cell research
Others
There are 15 Chapters to deeply display the global Circulating Tumor Cell Diagnostics market.
Chapter 1, to describe Circulating Tumor Cell Diagnostics Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Circulating Tumor Cell Diagnostics, with sales, revenue, and price of Circulating Tumor Cell Diagnostics, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Circulating Tumor Cell Diagnostics, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Circulating Tumor Cell Diagnostics market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Circulating Tumor Cell Diagnostics sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Circulating Tumor Cell Diagnostics Introduction
1.2 Market Analysis by Type
1.2.1 CTC Enrichment
1.2.2 CTC Detection
1.2.3 CTC Analysis
1.3 Market Analysis by Applications
1.3.1 Tumorigenesis research
1.3.2 EMT biomarkers development
1.3.3 Cancer stem cell research
1.3.4 Others
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Janssen Diagnostics
2.1.1 Business Overview
2.1.1.1 Janssen Diagnostics Description
2.1.1.2 Janssen Diagnostics Headquarter, Main Business and Finance Overview
2.1.2 Janssen Diagnostics Circulating Tumor Cell Diagnostics Product Introduction
2.1.2.1 Circulating Tumor Cell Diagnostics Production Bases, Sales Regions and Major Competitors
2.1.2.2 Circulating Tumor Cell Diagnostics Product Information
2.1.3 Janssen Diagnostics Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.1.3.1 Janssen Diagnostics Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.1.3.2 Global Janssen Diagnostics Circulating Tumor Cell Diagnostics Market Share in 2017
2.2 Advanced Cell Diagnostics
2.2.1 Business Overview
2.2.1.1 Advanced Cell Diagnostics Description
2.2.1.2 Advanced Cell Diagnostics Headquarter, Main Business and Finance Overview
2.2.2 Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Product Introduction
2.2.2.1 Circulating Tumor Cell Diagnostics Production Bases, Sales Regions and Major Competitors
2.2.2.2 Circulating Tumor Cell Diagnostics Product Information
2.2.3 Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2.3.1 Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2.3.2 Global Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Market Share in 2017
2.3 Aviva Biosciences
2.3.1 Business Overview
2.3.1.1 Aviva Biosciences Description
2.3.1.2 Aviva Biosciences Headquarter, Main Business and Finance Overview
2.3.2 Aviva Biosciences Circulating Tumor Cell Diagnostics Product Introduction
2.3.2.1 Circulating Tumor Cell Diagnostics Production Bases, Sales Regions and Major Competitors
2.3.2.2 Circulating Tumor Cell Diagnostics Product Information
2.3.3 Aviva Biosciences Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3.3.1 Aviva Biosciences Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3.3.2 Global Aviva Biosciences Circulating Tumor Cell Diagnostics Market Share in 2017
2.4 Biocept Inc
2.4.1 Business Overview
2.4.1.1 Biocept Inc Description
2.4.1.2 Biocept Inc Headquarter, Main Business and Finance Overview
2.4.2 Biocept Inc Circulating Tumor Cell Diagnostics Product Introduction
2.4.2.1 Circulating Tumor Cell Diagnostics Production Bases, Sales Regions and Major Competitors
2.4.2.2 Circulating Tumor Cell Diagnostics Product Information
2.4.3 Biocept Inc Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4.3.1 Biocept Inc Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4.3.2 Global Biocept Inc Circulating Tumor Cell Diagnostics Market Share in 2017
2.5 Biofluidica Inc.
2.5.1 Business Overview
2.5.1.1 Biofluidica Inc. Description
2.5.1.2 Biofluidica Inc. Headquarter, Main Business and Finance Overview
2.5.2 Biofluidica Inc. Circulating Tumor Cell Diagnostics Product Introduction
2.5.2.1 Circulating Tumor Cell Diagnostics Production Bases, Sales Regions and Major Competitors
2.5.2.2 Circulating Tumor Cell Diagnostics Product Information
2.5.3 Biofluidica Inc. Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5.3.1 Biofluidica Inc. Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5.3.2 Global Biofluidica Inc. Circulating Tumor Cell Diagnostics Market Share in 2017
2.6 CellTraffix Inc.
2.6.1 Business Overview
2.6.1.1 CellTraffix Inc. Description
2.6.1.2 CellTraffix Inc. Headquarter, Main Business and Finance Overview
2.6.2 CellTraffix Inc. Circulating Tumor Cell Diagnostics Product Introduction
2.6.2.1 Circulating Tumor Cell Diagnostics Production Bases, Sales Regions and Major Competitors
2.6.2.2 Circulating Tumor Cell Diagnostics Product Information
2.6.3 CellTraffix Inc. Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6.3.1 CellTraffix Inc. Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6.3.2 Global CellTraffix Inc. Circulating Tumor Cell Diagnostics Market Share in 2017
2.7 Clearbridge BioMedics Pte Ltd
2.7.1 Business Overview
2.7.1.1 Clearbridge BioMedics Pte Ltd Description
2.7.1.2 Clearbridge BioMedics Pte Ltd Headquarter, Main Business and Finance Overview
2.7.2 Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Product Introduction
2.7.2.1 Circulating Tumor Cell Diagnostics Production Bases, Sales Regions and Major Competitors
2.7.2.2 Circulating Tumor Cell Diagnostics Product Information
2.7.3 Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7.3.1 Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7.3.2 Global Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Market Share in 2017
2.8 Epic Sciences Inc.
2.8.1 Business Overview
2.8.1.1 Epic Sciences Inc. Description
2.8.1.2 Epic Sciences Inc. Headquarter, Main Business and Finance Overview
2.8.2 Epic Sciences Inc. Circulating Tumor Cell Diagnostics Product Introduction
2.8.2.1 Circulating Tumor Cell Diagnostics Production Bases, Sales Regions and Major Competitors
2.8.2.2 Circulating Tumor Cell Diagnostics Product Information
2.8.3 Epic Sciences Inc. Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8.3.1 Epic Sciences Inc. Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8.3.2 Global Epic Sciences Inc. Circulating Tumor Cell Diagnostics Market Share in 2017
2.9 Fluxion Biosciences Inc.
2.9.1 Business Overview
2.9.1.1 Fluxion Biosciences Inc. Description
2.9.1.2 Fluxion Biosciences Inc. Headquarter, Main Business and Finance Overview
2.9.2 Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Product Introduction
2.9.2.1 Circulating Tumor Cell Diagnostics Production Bases, Sales Regions and Major Competitors
2.9.2.2 Circulating Tumor Cell Diagnostics Product Information
2.9.3 Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9.3.1 Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9.3.2 Global Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Market Share in 2017
2.10 ScreenCell
2.10.1 Business Overview
2.10.1.1 ScreenCell Description
2.10.1.2 ScreenCell Headquarter, Main Business and Finance Overview
2.10.2 ScreenCell Circulating Tumor Cell Diagnostics Product Introduction
2.10.2.1 Circulating Tumor Cell Diagnostics Production Bases, Sales Regions and Major Competitors
2.10.2.2 Circulating Tumor Cell Diagnostics Product Information
2.10.3 ScreenCell Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10.3.1 ScreenCell Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10.3.2 Global ScreenCell Circulating Tumor Cell Diagnostics Market Share in 2017
2.11 Silicon Biosystems
2.11.1 Business Overview
2.11.2 Silicon Biosystems Circulating Tumor Cell Diagnostics Product Introduction
2.11.3 Silicon Biosystems Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.12 Sysmex Corporation
2.12.1 Business Overview
2.12.2 Sysmex Corporation Circulating Tumor Cell Diagnostics Product Introduction
2.12.3 Sysmex Corporation Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.13 Greiner Bio-One GmbH
2.13.1 Business Overview
2.13.2 Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Product Introduction
2.13.3 Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.14 AdnaGen AG
2.14.1 Business Overview
2.14.2 AdnaGen AG Circulating Tumor Cell Diagnostics Product Introduction
2.14.3 AdnaGen AG Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.15 Apocell Inc
2.15.1 Business Overview
2.15.2 Apocell Inc Circulating Tumor Cell Diagnostics Product Introduction
2.15.3 Apocell Inc Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.16 Biocep Ltd
2.16.1 Business Overview
2.16.2 Biocep Ltd Circulating Tumor Cell Diagnostics Product Introduction
2.16.3 Biocep Ltd Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.17 Canopus Bioscience Ltd
2.17.1 Business Overview
2.17.2 Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Product Introduction
2.17.3 Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.18 Creatv Microtech Inc
2.18.1 Business Overview
2.18.2 Creatv Microtech Inc Circulating Tumor Cell Diagnostics Product Introduction
2.18.3 Creatv Microtech Inc Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.19 Ikonisys Inc
2.19.1 Business Overview
2.19.2 Ikonisys Inc Circulating Tumor Cell Diagnostics Product Introduction
2.19.3 Ikonisys Inc Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.20 IV Diagnostics Inc
2.20.1 Business Overview
2.20.2 IV Diagnostics Inc Circulating Tumor Cell Diagnostics Product Introduction
2.20.3 IV Diagnostics Inc Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.21 Miltenyi Biotech GmbH
2.21.1 Business Overview
2.21.2 Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Product Introduction
2.21.3 Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.22 Nanostring Technologies Inc
2.22.1 Business Overview
2.22.2 Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Product Introduction
2.22.3 Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.23 Rarecells Diagnostics.
2.23.1 Business Overview
2.23.2 Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Product Introduction
2.23.3 Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.24 Vitatex Inc
2.24.1 Business Overview
2.24.2 Vitatex Inc Circulating Tumor Cell Diagnostics Product Introduction
2.24.3 Vitatex Inc Circulating Tumor Cell Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Circulating Tumor Cell Diagnostics Market Competition, by Manufacturer
3.1 Global Circulating Tumor Cell Diagnostics Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Circulating Tumor Cell Diagnostics Revenue and Market Share by Manufacturer (2016-2017)
3.3 Global Circulating Tumor Cell Diagnostics Price by Manufacturer (2016-2017)
3.4 Market Concentration Rate
3.4.1 Top 3 Circulating Tumor Cell Diagnostics Manufacturer Market Share in 2017
3.4.2 Top 5 Circulating Tumor Cell Diagnostics Manufacturer Market Share in 2017
3.5 Market Competition Trend
4 Global Circulating Tumor Cell Diagnostics Market Analysis by Regions
4.1 Global Circulating Tumor Cell Diagnostics Sales, Revenue and Market Share by Regions
4.1.1 Global Circulating Tumor Cell Diagnostics Sales by Regions (2013-2018)
4.1.2 Global Circulating Tumor Cell Diagnostics Revenue by Regions (2013-2018)
4.2 North America Circulating Tumor Cell Diagnostics Sales, Revenue and Growth Rate (2013-2018)
4.3 Europe Circulating Tumor Cell Diagnostics Sales, Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Circulating Tumor Cell Diagnostics Sales, Revenue and Growth Rate (2013-2018)
4.5 South America Circulating Tumor Cell Diagnostics Sales, Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Circulating Tumor Cell Diagnostics Sales, Revenue and Growth Rate (2013-2018)
5 North America Circulating Tumor Cell Diagnostics by Countries, Type, Application and Manufacturers
5.1 North America Circulating Tumor Cell Diagnostics Sales, Revenue and Market Share by Countries
5.1.1 North America Circulating Tumor Cell Diagnostics Sales by Countries (2013-2018)
5.1.2 North America Circulating Tumor Cell Diagnostics Revenue by Countries (2013-2018)
5.1.3 United States Circulating Tumor Cell Diagnostics Sales and Growth Rate (2013-2018)
5.1.4 Canada Circulating Tumor Cell Diagnostics Sales and Growth Rate (2013-2018)
5.1.5 Mexico Circulating Tumor Cell Diagnostics Sales and Growth Rate (2013-2018)
5.2 North America Circulating Tumor Cell Diagnostics Sales and Revenue (Value) by Manufacturers (2016-2017)
5.2.1 North America Circulating Tumor Cell Diagnostics Sales by Manufacturers (2016-2017)
5.2.2 North America Circulating Tumor Cell Diagnostics Revenue by Manufacturers (2016-2017)
5.3 North America Circulating Tumor Cell Diagnostics Sales, Revenue and Market Share by Type (2013-2018)
5.3.1 North America Circulating Tumor Cell Diagnostics Sales and Sales Share by Type (2013-2018)
5.3.2 North America Circulating Tumor Cell Diagnostics Revenue and Revenue Share by Type (2013-2018)
5.4 North America Circulating Tumor Cell Diagnostics Sales, Revenue and Market Share by Application (2013-2018)
5.4.1 North America Circulating Tumor Cell Diagnostics Sales and Sales Share by Application (2013-2018)
5.4.2 North America Circulating Tumor Cell Diagnostics Revenue and Revenue Share by Application (2013-2018)
6 Europe Circulating Tumor Cell Diagnostics by Countries, Type, Application and Manufacturers
6.1 Europe Circulating Tumor Cell Diagnostics Sales, Revenue and Market Share by Countries
6.1.1 Europe Circulating Tumor Cell Diagnostics Sales by Countries (2013-2018)
6.1.2 Europe Circulating Tumor Cell Diagnostics Revenue by Countries (2013-2018)
6.1.3 Germany Circulating Tumor Cell Diagnostics Sales and Growth Rate (2013-2018)
6.1.4 UK Circulating Tumor Cell Diagnostics Sales and Growth Rate (2013-2018)
6.1.5 France Circulating Tumor Cell Diagnostics Sales and Growth Rate (2013-2018)
6.1.6 Russia Circulating Tumor Cell Diagnostics Sales and Growth Rate (2013-2018)
6.1.7 Italy Circulating Tumor Cell Diagnostics Sales and Growth Rate (2013-2018)
6.2 Europe Circulating Tumor Cell Diagnostics Sales and Revenue (Value) by Manufacturers (2016-2017)
6.2.1 Europe Circulating Tumor Cell Diagnostics Sales by Manufacturers (2016-2017)
6.2.2 Europe Circulating Tumor Cell Diagnostics Revenue by Manufacturers (2016-2017)
6.3 Europe Circulating Tumor Cell Diagnostics Sales, Revenue and Market Share by Type (2013-2018)
6.3.1 Europe Circulating Tumor Cell Diagnostics Sales and Sales Share by Type (2013-2018)
6.3.2 Europe Circulating Tumor Cell Diagnostics Revenue and Revenue Share by Type (2013-2018)
6.4 Europe Circulating Tumor Cell Diagnostics Sales, Revenue and Market Share by Application (2013-2018)
6.4.1 Europe Circulating Tumor Cell Diagnostics Sales and Sales Share by Application (2013-2018)
6.4.2 Europe Circulating Tumor Cell Diagnostics Revenue and Revenue Share by Application (2013-2018)
7 Asia-Pacific Circulating Tumor Cell Diagnostics by Countries, Type, Application and Manufacturers
7.1 Asia-Pacific Circulating Tumor Cell Diagnostics Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Circulating Tumor Cell Diagnostics Sales by Countries (2013-2018)
7.1.2 Asia-Pacific Circulating Tumor Cell Diagnostics Revenue by Countries (2013-2018)
7.1.3 China Circulating Tumor Cell Diagnostics Sales and Growth Rate (2013-2018)
7.1.4 Japan Circulating Tumor Cell Diagnostics Sales and Growth Rate (2013-2018)
7.1.5 Korea Circulating Tumor Cell Diagnostics Sales and Growth Rate (2013-2018)
7.1.6 India Circulating Tumor Cell Diagnostics Sales and Growth Rate (2013-2018)
7.1.7 Southeast Asia Circulating Tumor Cell Diagnostics Sales and Growth Rate (2013-2018)
7.2 Asia-Pacific Circulating Tumor Cell Diagnostics Sales and Revenue (Value) by Manufacturers (2016-2017)
7.2.1 Asia-Pacific Circulating Tumor Cell Diagnostics Sales by Manufacturers (2016-2017)
7.2.2 Asia-Pacific Circulating Tumor Cell Diagnostics Revenue by Manufacturers (2016-2017)
7.3 Asia-Pacific Circulating Tumor Cell Diagnostics Sales, Revenue and Market Share by Type (2013-2018)
7.3.1 Asia-Pacific Circulating Tumor Cell Diagnostics Sales and Sales Share by Type (2013-2018)
7.3.2 Asia-Pacific Circulating Tumor Cell Diagnostics Revenue and Revenue Share by Type (2013-2018)
7.4 Asia-Pacific Circulating Tumor Cell Diagnostics Sales, Revenue and Market Share by Application (2013-2018)
7.4.1 Asia-Pacific Circulating Tumor Cell Diagnostics Sales and Sales Share by Application (2013-2018)
7.4.2 Asia-Pacific Circulating Tumor Cell Diagnostics Revenue and Revenue Share by Application (2013-2018)
8 South America Circulating Tumor Cell Diagnostics by Countries, Type, Application and Manufacturers
8.1 South America Circulating Tumor Cell Diagnostics Sales, Revenue and Market Share by Countries
8.1.1 South America Circulating Tumor Cell Diagnostics Sales by Countries (2013-2018)
8.1.2 South America Circulating Tumor Cell Diagnostics Revenue by Countries (2013-2018)
8.1.3 Brazil Circulating Tumor Cell Diagnostics Sales and Growth Rate (2013-2018)
8.1.4 Argentina Circulating Tumor Cell Diagnostics Sales and Growth Rate (2013-2018)
8.1.5 Colombia Circulating Tumor Cell Diagnostics Sales and Growth Rate (2013-2018)
8.2 South America Circulating Tumor Cell Diagnostics Sales and Revenue (Value) by Manufacturers (2016-2017)
8.2.1 South America Circulating Tumor Cell Diagnostics Sales by Manufacturers (2016-2017)
8.2.2 South America Circulating Tumor Cell Diagnostics Revenue by Manufacturers (2016-2017)
8.3 South America Circulating Tumor Cell Diagnostics Sales, Revenue and Market Share by Type (2013-2018)
8.3.1 South America Circulating Tumor Cell Diagnostics Sales and Sales Share by Type (2013-2018)
8.3.2 South America Circulating Tumor Cell Diagnostics Revenue and Revenue Share by Type (2013-2018)
8.4 South America Circulating Tumor Cell Diagnostics Sales, Revenue and Market Share by Application (2013-2018)
8.4.1 South America Circulating Tumor Cell Diagnostics Sales and Sales Share by Application (2013-2018)
8.4.2 South America Circulating Tumor Cell Diagnostics Revenue and Revenue Share by Application (2013-2018)
9 Middle East and Africa Circulating Tumor Cell Diagnostics by Countries, Type, Application and Manufacturers
9.1 Middle East and Africa Circulating Tumor Cell Diagnostics Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Circulating Tumor Cell Diagnostics Sales by Countries (2013-2018)
9.1.2 Middle East and Africa Circulating Tumor Cell Diagnostics Revenue by Countries (2013-2018)
9.1.3 Saudi Arabia Circulating Tumor Cell Diagnostics Sales and Growth Rate (2013-2018)
9.1.4 UAE Circulating Tumor Cell Diagnostics Sales and Growth Rate (2013-2018)
9.1.5 Egypt Circulating Tumor Cell Diagnostics Sales and Growth Rate (2013-2018)
9.1.6 Nigeria Circulating Tumor Cell Diagnostics Sales and Growth Rate (2013-2018)
9.1.7 South Africa Circulating Tumor Cell Diagnostics Sales and Growth Rate (2013-2018)
9.2 Middle East and Africa Circulating Tumor Cell Diagnostics Sales and Revenue (Value) by Manufacturers (2016-2017)
9.2.1 Middle East and Africa Circulating Tumor Cell Diagnostics Sales by Manufacturers (2016-2017)
9.2.2 Middle East and Africa Circulating Tumor Cell Diagnostics Revenue by Manufacturers (2016-2017)
9.3 Middle East and Africa Circulating Tumor Cell Diagnostics Sales, Revenue and Market Share by Type (2013-2018)
9.3.1 Middle East and Africa Circulating Tumor Cell Diagnostics Sales and Sales Share by Type (2013-2018)
9.3.1 Middle East and Africa Circulating Tumor Cell Diagnostics Revenue and Revenue Share by Type (2013-2018)
9.4 Middle East and Africa Circulating Tumor Cell Diagnostics Sales, Revenue and Market Share by Application (2013-2018)
9.4.1 Middle East and Africa Circulating Tumor Cell Diagnostics Sales and Sales Share by Application (2013-2018)
9.4.2 Middle East and Africa Circulating Tumor Cell Diagnostics Revenue and Revenue Share by Application (2013-2018)
10 Global Circulating Tumor Cell Diagnostics Market Segment by Type
10.1 Global Circulating Tumor Cell Diagnostics Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Circulating Tumor Cell Diagnostics Sales and Market Share by Type (2013-2018)
10.1.2 Global Circulating Tumor Cell Diagnostics Revenue and Market Share by Type (2013-2018)
10.2 CTC Enrichment Sales Growth and Price
10.2.1 Global CTC Enrichment Sales Growth (2013-2018)
10.2.2 Global CTC Enrichment Price (2013-2018)
10.3 CTC Detection Sales Growth and Price
10.3.1 Global CTC Detection Sales Growth (2013-2018)
10.3.2 Global CTC Detection Price (2013-2018)
10.4 CTC Analysis Sales Growth and Price
10.4.1 Global CTC Analysis Sales Growth (2013-2018)
10.4.2 Global CTC Analysis Price (2013-2018)
11 Global Circulating Tumor Cell Diagnostics Market Segment by Application
11.1 Global Circulating Tumor Cell Diagnostics Sales Market Share by Application (2013-2018)
11.2 Tumorigenesis research Sales Growth (2013-2018)
11.3 EMT biomarkers development Sales Growth (2013-2018)
11.4 Cancer stem cell research Sales Growth (2013-2018)
11.5 Others Sales Growth (2013-2018)
12 Circulating Tumor Cell Diagnostics Market Forecast (2018-2023)
12.1 Global Circulating Tumor Cell Diagnostics Sales, Revenue and Growth Rate (2018-2023)
12.2 Circulating Tumor Cell Diagnostics Market Forecast by Regions (2018-2023)
12.2.1 North America Circulating Tumor Cell Diagnostics Market Forecast (2018-2023)
12.2.2 Europe Circulating Tumor Cell Diagnostics Market Forecast (2018-2023)
12.2.3 Asia-Pacific Circulating Tumor Cell Diagnostics Market Forecast (2018-2023)
12.2.4 South America Circulating Tumor Cell Diagnostics Market Forecast (2018-2023)
12.2.5 Middle East and Africa Circulating Tumor Cell Diagnostics Market Forecast (2018-2023)
12.3 Circulating Tumor Cell Diagnostics Market Forecast by Type (2018-2023)
12.3.1 Global Circulating Tumor Cell Diagnostics Sales Forecast by Type (2018-2023)
12.3.2 Global Circulating Tumor Cell Diagnostics Market Share Forecast by Type (2018-2023)
12.4 Circulating Tumor Cell Diagnostics Market Forecast by Application (2018-2023)
12.4.1 Global Circulating Tumor Cell Diagnostics Sales Forecast by Application (2018-2023)
12.4.2 Global Circulating Tumor Cell Diagnostics Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Circulating Tumor Cell Diagnostics Picture
Table Product Specifications of Circulating Tumor Cell Diagnostics
Figure Global Circulating Tumor Cell Diagnostics CAGR (
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
